Insider buying last 90 days
No open-market insider purchases were filed for IDXX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
IDEXX Laboratories closed at $704.23 on 13 November 2026, +0.9% on the day. The price sits between the 50-day ($562.41) and 200-day ($572.35) moving averages, inside a 52-week range of $500.61 to $769.98. The GekkoIndex reads 46.7, in the Neutral zone, up 4.4 points over five sessions. Gekko Fair Value is $542.17, so the price is 29.9% above it.
The next earnings report is due on 1 February 2027, 78 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 10.9% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Seasonally, the next 20 trading days from this point averaged +5.4% over the last 5 years, rising in 4 of them.
7 firms rate the stock: 5 buy, 2 hold and 0 sell, with a consensus target of $717.17. A typical daily move is about 4.6%, and a typical 20-day move about 5.2%. On the swing-trade checklist, 3 items read supportive and 1 reads as a headwind (fair value).
A plain summary of the figures as of the Nov 13, 2026 close.
IDEXX Laboratories scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Averages disagree
Close $704.23 sits between the 50-day ($562.41) and 200-day ($572.35) averages, or the averages disagree.
See the chart46.7, Neutral
Reading 46.7 is in the Neutral zone.
See the GekkoIndex29.2% above
Price is 29.2% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 78 days
Next report Feb 1, 2027, 78 days away — outside a typical 20-trading-day hold.
See earnings+4.8% on average
From this point in the calendar, the next 20 trading days averaged +4.8% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
IDEXX Laboratories closed at $704.23 on Nov 13, 2026, −1.3% over the past year, inside a 52-week range of $500.61 to $769.98.
Use the left and right arrow keys to read daily values.
Put IDXX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
IDEXX Laboratories develops and sells diagnostic products and services used mainly by veterinary practices, along with buyers in livestock, poultry, dairy, and water testing. It is widely recognized for its veterinary diagnostics, including point-of-care instruments, consumables, and rapid assay kits used to test companion animals, alongside laboratory testing and consultation work, imaging tools, and practice management software for clinics.
The business is arranged into groups covering companion animal diagnostics, water quality testing, and livestock, poultry, and dairy health monitoring, with further offerings beyond these core areas. Its water testing line includes tests such as Colilert, Colilert-18, Colisure, Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray, used to check for contaminants like coliforms and E. coli. IDEXX also makes instruments for blood gas and electrolyte analysis, chemistry and hematology testing, and SARS-CoV-2 RT-PCR tests, reaching both veterinary and human diagnostic customers, including independent clinics and larger veterinary groups. Sales run through its own marketing, service, and technical teams, as well as outside distributors and resellers.
Founded in 1983, IDEXX Laboratories is headquartered in Westbrook, Maine, and its shares are listed on the NASDAQ under the ticker IDXX.
IDEXX Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.7, in the Neutral zone, up 4.4 points over five sessions.
Up 4.4 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +0.1% | +1.7% | ||
| Accumulation | 280 | +0.2% | +0.5% | ||
| Neutral (current zone) | 352 | +0.4% | +0.3% | ||
| Distribution | 35 | −0.1% | +2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average IDXX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
IDEXX Laboratories trades 29.2% above Gekko Fair Value of $544.88, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what IDEXX Laboratories shares are worth, recalculated every trading day.
$544.88
Gekko Fair Value, Nov 14, 2026
29.2% Overvalued
At the end of Aug 2026 the price was 20.8% above the estimate.
No open-market insider purchases were filed for IDEXX Laboratories, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for IDXX in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 25 |
From congressional disclosures, which report amounts as ranges.
IDEXX Laboratories has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold IDXX.
IDEXX Laboratories reports on Feb 1, 2027, before the open (78 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 1, 2027
Expected before the open, 78 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | $3.96 est $3.73 | $1.21B est $1.19B | +21.9% |
| Aug 4, 2026 | $4.27 est $3.95 | $1.22B est $1.20B | +3.0% |
| May 5, 2026 | $3.47 est $3.41 | $1.14B est $1.12B | +2.9% |
| Feb 2, 2026 | $3.08 est $2.94 | $1.09B est $1.07B | −5.7% |
| Nov 3, 2025 | $3.40 est $3.14 | $1.11B est $1.07B | +14.7% |
| Aug 4, 2025 | $3.63 est $3.28 | $1.11B est $1.06B | +19.9% |
| May 1, 2025 | $2.96 est $2.85 | $998.4M est $997.1M | +9.1% |
| Feb 3, 2025 | $2.62 est $2.39 | $954.3M est $935.1M | +10.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for IDEXX Laboratories is $717.17, +1.8% from the last close, from 7 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 7 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 3 | Jefferies | $770 | +9.3% |
| Nov 3 | UBS | $700 | −0.6% |
| Nov 3 | Morgan Stanley | $810 | +15.0% |
| Nov 3 | Stifel Nicolaus | $700 | −0.6% |
| Nov 2 | Morgan Stanley | $805 | +14.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, IDEXX Laboratories averaged +4.8% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 3 of 5 |
| Next 10 trading days | +0.1% | 2 of 5 |
| Next 15 trading days | +2.5% | 2 of 5 |
| Next 20 trading days | +4.8% | 4 of 5 |
| Next 30 trading days | +3.5% | 2 of 5 |
For scale, IDXX’s typical 20-trading-day move in either direction is about 5.2%.
IDEXX Laboratories’s market cap is $55.48B, with a P/E ratio of 47 and revenue of $4.66B over the last twelve months.
Coverage of IDEXX Laboratories this week reads neutral: 1 positive, 4 neutral and 2 negative headlines.
IDEXX Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
IDEXX Laboratories’s market cap is $55.48B at the Nov 13, 2026 close of $704.23, with 78.79M shares outstanding. The shares trade on a P/E ratio of 47.
The consensus analyst 12-month price target for IDEXX Laboratories is $717.17, +1.8% from the last close. Of the 7 firms that rated the stock in the last 90 days, 5 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate IDEXX Laboratories is overvalued: the Nov 13, 2026 close of $704.23 is 29.2% above Gekko Fair Value of $544.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
IDEXX Laboratories is expected to report on Feb 1, 2027, before the market opens (78 days away). Analysts expect earnings of $3.30 per share on revenue of $1.18B. IDEXX Laboratories beat the earnings estimate in 8 of its last 8 reports, moving 10.9% on average across the report.
IDEXX Laboratories’s 52-week high is $769.98 and its 52-week low is $500.61; it closed at $704.23 on Nov 13, 2026, −1.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.